WFG Advisors’s Myriad Genetics MYGN Stock Holding History

WFG Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$52K	Hold	2,000	–	–	0.01%	692
2017 Q1	$38K	Hold	2,000	–	–	0.01%	732
2016 Q4	$33K	Buy	2,000 +861	+76%	+$15.6K	0.01%	819
2016 Q3	$23K	Buy	1,139 +500	+78%	+$12.7K	0.01%	914
2016 Q2	$20K	Hold	639	–	–	0.01%	915
2016 Q1	$24K	Hold	639	–	–	0.01%	841
2015 Q4	$28K	Hold	639	–	–	0.01%	815
2015 Q3	$24K	Buy	639 +139	+28%	+$4.93K	0.01%	842
2015 Q2	$17K	Hold	500	–	–	﹤0.01%	1034
2015 Q1	$18K	Hold	500	–	–	0.01%	1023
2014 Q4	$17K	Hold	500	–	–	﹤0.01%	1285
2014 Q3	$19K	Hold	500	–	–	﹤0.01%	1296
2014 Q2	$19K	Hold	500	–	–	﹤0.01%	1300
2014 Q1	$17K	Hold	500	–	–	﹤0.01%	1307
2013 Q4	$10K	Buy	+500	New	+$12.6K	﹤0.01%	1581

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

WFG Advisors's MYGN Position: Q2 2017 in Review

WFG Advisors held its Myriad Genetics (MYGN) position steady in Q2 2017 at 2,000 shares worth $52K. The position accounts for 0.01% of the portfolio, ranked #692.

WFG Advisors first reported a position in MYGN in Q4 2013 and has held it in 15 quarters since. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

WFG Advisors held 2,000 shares of Myriad Genetics worth $52K as of Q2 2017.
WFG Advisors left its Myriad Genetics share count unchanged in Q2 2017.
Myriad Genetics made up 0.01% of WFG Advisors's portfolio in Q2 2017, its #692 holding.
WFG Advisors first reported a position in Myriad Genetics in Q4 2013 and has held it in 15 quarters since.
239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.